Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Publication year range
1.
Exp Hematol ; 29(4): 458-70, 2001 Apr.
Article in English | MEDLINE | ID: mdl-11301186

ABSTRACT

Some phenotypic and functional properties of lymphocytes from bone marrow or peripheral blood stem cell donors were compared in a randomized study. Lymphocyte subsets were analyzed by immunocytometry in blood harvested from bone marrow donors (n = 27) and from peripheral blood stem cell donors before and after granulocyte colony-stimulating factor mobilization (n = 23) and in bone marrow and peripheral blood stem cell grafts. Granulocyte colony-stimulating factor mobilization increased the blood T and B, but not NK, lymphocyte counts. All lymphocyte counts were approximately 10-fold higher in peripheral blood stem cell grafts than in bone marrow grafts. Analysis of CD25, CD95, HLA-DR, and CD45RA expression shows that T-cell activation level was lower after granulocyte colony-stimulating factor mobilization. Similarly, granulocyte colony-stimulating factor reduced by twofold to threefold the percentage of interferon-gamma, interleukin-2, and tumor necrosis factor-alpha-secreting cells within the NK, NK-T, and T-cell subsets and severely impaired the potential for interferon-gamma production at the single-cell level. mRNA levels of both type 1 (interferon-gamma, interleukin-2) and type 2 (interleukin-4, interleukin-13) cytokines were approximately 10-fold lower in peripheral blood stem cell grafts than in bone marrow grafts. This reduced potential of cytokine production was not associated with a preferential mobilization of so-called "suppressive" cells (CD3+CD4-CD8-, CD3+CD8+CD56+, or CD3+TCRVA24+CD161+), nor with a modulation of killer cell receptors CD161, NKB1, and CD94 expression by NK, NK-T, or T cells. Our data demonstrate in a randomized setting that quantitative as well as qualitative differences exist between a bone marrow and a peripheral blood stem cell graft, whose ability to produce type 1 and type 2 cytokines is impaired.


Subject(s)
Granulocyte Colony-Stimulating Factor/pharmacology , Lymphocyte Count , Lymphocyte Subsets/immunology , Phenotype , B-Lymphocytes/immunology , Blood Donors , Bone Marrow Transplantation , HLA-DR Antigens/analysis , Hematopoietic Stem Cell Transplantation , Humans , Immunophenotyping , Interferon-gamma/biosynthesis , Interferon-gamma/genetics , Interleukin-13/genetics , Interleukin-2/biosynthesis , Interleukin-2/genetics , Interleukin-4/genetics , Killer Cells, Natural/immunology , Leukocyte Common Antigens/analysis , Lymphocyte Activation , Protein Tyrosine Phosphatase, Non-Receptor Type 1 , RNA, Messenger/analysis , Receptors, Interleukin-2/analysis , T-Lymphocytes/immunology , T-Lymphocytes, Regulatory/immunology , Tissue Donors , Tumor Necrosis Factor-alpha/biosynthesis , Tumor Necrosis Factor-alpha/genetics , fas Receptor/analysis
2.
Blood ; 97(1): 63-72, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11133743

ABSTRACT

Administration of donor T cells expressing the herpes simplex-thymidine kinase (HS-tk) with a hematopoietic stem cell (HSC) transplantation could allow, if graft-versus-host disease (GVHD) was to occur, a selective in vivo depletion of these T cells by the use of ganciclovir (GCV). The study evaluates the feasibility of such an approach. Escalating numbers of donor HS-tk-expressing CD3(+) gene-modified cells (GMCs) are infused with a T-cell-depleted bone marrow transplantation (BMT). Twelve patients with hematological malignancies received 2 x 10(5) (n = 5), 6 x 10(5) (n = 5), or 20 x 10(5) (n = 2) donor CD3(+) GMCs/kg with a BMT from a human leukocyte antigen (HLA)-identical sibling. No acute toxicity was associated with GMC administration. An early increase of circulating GMCs followed by a progressive decrease and long-lasting circulation of GMCs was documented. GCV treatment resulted in significant rapid decrease in circulating GMCs. Three patients developed acute GVHD, with a grade of at least II, while one patient developed chronic GVHD. Treatment with GCV alone was associated with a complete remission (CR) in 2 patients with acute GVHD, while the addition of glucocorticoids was necessary to achieve a CR in the last case. Long-lasting CR occurred with GCV treatment in the patient with chronic GVHD. Unfortunately, Epstein-Barr virus-lymphoproliferative disease occurred in 3 patients. Overall, the administration of low numbers of HS-tk-expressing T cells early following an HLA-identical BMT is associated with no acute toxicity, persistent circulation of the GMCs, and GCV-sensitive GVHD. Such findings open the way to the infusion of higher numbers of gene-modified donor T cells to enhance post-BMT immune competence while preserving GCV-sensitive alloreactivity.


Subject(s)
Bone Marrow Transplantation/methods , Lymphocyte Depletion/methods , T-Lymphocytes/transplantation , Thymidine Kinase/administration & dosage , Adult , Antiviral Agents/administration & dosage , Antiviral Agents/pharmacology , Bone Marrow Transplantation/immunology , CD3 Complex , Cell Culture Techniques , Disease-Free Survival , Epstein-Barr Virus Infections/complications , Female , Ganciclovir/administration & dosage , Ganciclovir/pharmacology , Graft Survival , Graft vs Host Disease/prevention & control , Graft vs Host Disease/therapy , Herpes Simplex/drug therapy , Herpes Simplex/enzymology , Humans , Lymphoproliferative Disorders/virology , Male , Middle Aged , Survival Rate , T-Lymphocytes/drug effects , T-Lymphocytes/virology , Thymidine Kinase/drug effects , Thymidine Kinase/genetics , Thymidine Kinase/therapeutic use , Time Factors , Transfection , Transplantation, Homologous/methods , Treatment Outcome , Viral Proteins/drug effects , Viral Proteins/genetics , Viral Proteins/therapeutic use
3.
Transfus Clin Biol ; 6(6): 409-17, 1999 Dec.
Article in French | MEDLINE | ID: mdl-10666799

ABSTRACT

A phase I clinical trial is being currently performed in our institution, aiming at evaluating the feasibility and toxicity related to the administration of Herpes Simplex-thymidine kinase gene-expressing human primary T lymphocytes following allogeneic hematopoietic stem cell transplantation. The need for safe and standardized preparation conditions for gene-modified cells is crucial. We describe the closed culture system used in the current trial for ex vivo retroviral-mediated gene transfer and transduced cell selection. Cell handling is performed in closed systems using sampling and transfer pack bags, culture bags and a sterile connection device which avoids opening the culture system. This closed system allows safe and reproducible ex vivo preparation of gene-modified primary T-lymphocytes for clinical use.


Subject(s)
Cell Culture Techniques/methods , Genetic Therapy/methods , Genetic Vectors/genetics , Hematopoietic Stem Cell Transplantation/methods , Simplexvirus/genetics , Thymidine Kinase/genetics , Viral Proteins/genetics , Cell Culture Techniques/instrumentation , Cells, Cultured/transplantation , Cells, Cultured/virology , Centrifugation/methods , Equipment Contamination/prevention & control , Forms and Records Control , Genetic Therapy/instrumentation , Hematopoietic Stem Cell Transplantation/instrumentation , Hematopoietic Stem Cells/enzymology , Hematopoietic Stem Cells/virology , Humans , Quality Control , Safety , Simplexvirus/enzymology , Sterilization , T-Lymphocytes/enzymology , T-Lymphocytes/virology
4.
Cell Mol Biol ; 38(2): 181-7, 1992 Apr.
Article in English | MEDLINE | ID: mdl-1571947

ABSTRACT

All the RNAs were extracted separately from the gonads and digestive glands of the garden snail Helix aspersa. After separation by oligo-dT-cellulose chromatography, the mRNA were evaluated using optical density measurements and agarose gel electrophoretic analysis and then used in a cell-free translation system: a rabbit reticulocyte lysate added with 35S methionine. The in vitro synthesized proteins were characterized by immunoprecipitation with polyclonal antibodies which were raised against mature oocyte proteins. The proteins were then evaluated quantitatively using liquid scintillation counting and qualitatively using SDS polyacrylamide gel electrophoresis and fluorography. The results demonstrated that the digestive gland of the garden snail is a vitellogenin synthesis site.


Subject(s)
Digestive System/metabolism , Helix, Snails/metabolism , Vitellogenesis , Animals , Cell-Free System , Gonads/metabolism , In Vitro Techniques , Oocytes/immunology , Precipitin Tests , RNA, Messenger/metabolism
5.
Cell Mol Biol ; 37(6): 639-50, 1991.
Article in English | MEDLINE | ID: mdl-1747899

ABSTRACT

Three major yolk proteins of 140, 100, 80 KD and a faint band of 440 KD were determined by gradient gel electrophoresis in the mature eggs of Helix aspersa. Polyclonal and monoclonal antibodies were raised against mature oocyte extracts. The binding sites of these rabbit and hybridoma antibodies with the different yolk protein components were identified with a combination of WESTERN blotting, ELISA, immunofluorescence and immunogold staining. All these techniques demonstrated materials immunologically similar to vitellins in the hemolymph and in the glandular cells of the digestive gland. The data suggest that, for its vitellogenesis, the garden-snail utilizes a heterosynthetic mechanism similar to that known in oviparous animals. The vitellogenins would be produced by the digestive gland.


Subject(s)
Egg Proteins/analysis , Helix, Snails/chemistry , Oocytes/chemistry , Protein Precursors/analysis , Animals , Antibodies, Monoclonal , Digestive System/chemistry , Electrophoresis, Polyacrylamide Gel , Enzyme-Linked Immunosorbent Assay , Fluorescent Antibody Technique , Hemolymph/chemistry , Immunohistochemistry , Vitellogenins/analysis
SELECTION OF CITATIONS
SEARCH DETAIL
...